Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach.
暂无分享,去创建一个
[1] M. Schemper,et al. Predictive Accuracy and Explained Variation in Cox Regression , 2000, Biometrics.
[2] C. McCulloch,et al. Latent Class Models for Joint Analysis of Longitudinal Biomarker and Event Process Data , 2002 .
[3] Menggang Yu,et al. Individualized predictions of disease progression following radiation therapy for prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] P. Heagerty,et al. Survival Model Predictive Accuracy and ROC Curves , 2005, Biometrics.
[5] Ian M Thompson,et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.
[6] J. Ware,et al. Random-effects models for longitudinal data. , 1982, Biometrics.
[7] H. V. Houwelingen. Dynamic Prediction by Landmarking in Event History Analysis , 2007 .
[8] Robert C. Frazier,et al. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy , 1999, Cancer.
[9] R. Prentice. Covariate measurement errors and parameter estimation in a failure time regression model , 1982 .
[10] Cécile Proust-Lima,et al. Joint modelling of multivariate longitudinal outcomes and a time-to-event: A nonlinear latent class approach , 2009, Comput. Stat. Data Anal..
[11] Cécile Proust-Lima,et al. Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts. , 2008, International journal of radiation oncology, biology, physics.
[12] E Graf,et al. Assessment and comparison of prognostic classification schemes for survival data. , 1999, Statistics in medicine.
[13] Paul Schellhammer,et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.
[14] D. Pauler,et al. Predicting time to prostate cancer recurrence based on joint models for non‐linear longitudinal biomarkers and event time outcomes , 2002, Statistics in medicine.
[15] A. D'Amico,et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. , 2004, The Journal of urology.
[16] J. Purdy,et al. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. , 2004, International journal of radiation oncology, biology, physics.
[17] D G Altman,et al. What do we mean by validating a prognostic model? , 2000, Statistics in medicine.
[18] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[19] M. Wulfsohn,et al. Modeling the Relationship of Survival to Longitudinal Data Measured with Error. Applications to Survival and CD4 Counts in Patients with AIDS , 1995 .
[20] Yingye Zheng,et al. Prospective Accuracy for Longitudinal Markers , 2007, Biometrics.
[21] Menggang Yu,et al. JOINT LONGITUDINAL-SURVIVAL-CURE MODELS AND THEIR APPLICATION TO PROSTATE CANCER , 2004 .
[22] Cécile Proust-Lima,et al. Determinants of change of prostate-specific antigen over time and its association with recurrence following external beam radiation therapy of prostate cancer in 5 large cohorts , 2010 .
[23] R Henderson,et al. Joint modelling of longitudinal measurements and event time data. , 2000, Biostatistics.
[24] E Graf,et al. Quantifying the Predictive Performance of Prognostic Models for Censored Survival Data with Time‐Dependent Covariates , 2008, Biometrics.
[25] J M Taylor,et al. Replacing time since human immunodeficiency virus infection by marker values in predicting residual time to acquired immunodeficiency syndrome diagnosis. Multicenter AIDS Cohort Study. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[26] Robin Henderson,et al. Identification and efficacy of longitudinal markers for survival. , 2002, Biostatistics.
[27] Yingye Zheng,et al. Partly Conditional Survival Models for Longitudinal Data , 2005, Biometrics.
[28] D. Marquardt. An Algorithm for Least-Squares Estimation of Nonlinear Parameters , 1963 .
[29] P. Carroll,et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower , 2005 .
[30] H M Sandler,et al. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. , 1997, International journal of radiation oncology, biology, physics.
[31] G. Schwarz. Estimating the Dimension of a Model , 1978 .
[32] D. M. Allen,et al. Determining the number of components in mixtures of linear models , 2001 .